|
|
|
Digital Mammography
and Radiography |
| |
CompuMed’s DICOM
OsteoGram® Featured in Combination with Digital Mammography and
Radiography at RSNA
Other Topics:
Emergency Department Information
Systems
CompuMed, Inc.
December 11, 2006
Kodak, Fuji and Swissray International Demo Imaging Systems
Integrated with CompuMed’s Pioneering Osteoporosis Screening
Software
Los Angeles, CA -- CompuMed, Inc. (OTCBB:CMPD) -- a medical
informatics company leading the development of advanced imaging
technology for cost effective analysis and monitoring –
demonstrated its DICOM OsteoGram in tandem with imaging systems
from several major vendors during the 92nd Scientific Assembly
and Annual Meeting of the Radiological Society of North America,
held in Chicago November 26-30. |
| |
|
|
| |
The OsteoGram
system has applications across a broad spectrum of digital
platforms, and was featured in conjunction with digital
radiography (DR), computed radiography (CR) and digital
mammography systems from CompuMed licensing partners including
the Eastman Kodak Company, Fujifilm Medical Systems USA and
Swissray International.
The DICOM OsteoGram represents the latest advancement to
CompuMed's ground-breaking software-based imaging system for
screening, diagnosing and monitoring osteoporosis. It uses a
digital image derived from filmless x-ray equipment to enable
clinicians to perform accurate and precise osteoporosis testing.
DICOM (Digital Communications and Imaging in Medicine) is the
information standard that allows the new generation of medical
imaging equipment to interconnect. DICOM-based systems, such as
filmless x-ray and digital mammography platforms, have become a
high growth segment of the medical imaging market.
"Coupling the OsteoGram with digital mammography has the
potential to be an especially winning combination,” said
CompuMed CEO Jerry McLaughlin. “Imagine that women could obtain
a bone density test at the same time and on the same equipment
as their mammogram.”
Osteoporosis is a silent disease that affects more than 200
million people worldwide. According to the National Osteoporosis
Foundation, the costs associated with treating the complications
of osteoporosis exceed $17 billion in the United States alone.
Medicare’s HEDIS 2004 program directs health care plan providers
to test for underlying bone disease when a woman shows up with a
fragility fracture. Osteoporosis can often be controlled with
calcium supplements and life-style changes if low bone density
is detected in the early stages.
“We were pleased to participate with our partners at RSNA,”
added McLaughlin. “Computer aided detection [CAD] is a growing
field, and we are proud to help pioneer the development and
integration of applications that make life easier for busy
radiologists and add convenience for patients. In the future, we
intend to add other CAD applications, many of which will enable
an ASP model with recurring revenues for CompuMed.”
About RSNA:
The RSNA annual meeting is the premier international forum
for radiologic science and technology. The scientific and
educational program includes presentations in all radiologic
subspecialties through scientific papers and posters, refresher
courses, honored lectures, education exhibits, infoRAD exhibits,
symposia and technical exhibits. More than 62,000 people attend
RSNA, making it the world’s largest medical assembly. Attendees
include radiology professionals, hospital and corporate-based
healthcare executives and exhibitor personnel from greater than
700 exhibits.
About CompuMed
Founded in 1973, CompuMed, Inc. (OTCBB:CMPD) is leading the
development of advanced imaging and medical informatics
solutions that provide cost effective analysis and monitoring.
CompuMed focuses on cardiovascular and musculoskeletal diseases,
as well as other diseases associated with aging populations. Its
unique expertise in telemonitoring, imaging and analysis
facilitates the development of new solutions and services
designed to improve healthcare provider workflow and patient
care, while reducing costs. CompuMed's core products, the
OsteoGram® and CardioGramTM systems, are cleared by the FDA and
reimbursable by Medicare. The OsteoGram is an accurate and
precise technology for osteoporosis testing. The underlying
OsteoGram technology has significant cost advantages over other
technologies and will be applied to a suite of value-added
applications, such as following the progression of arthritic
disease and diagnosing vertebral fractures and scoliosis. The
CardioGram system is one of the first telecommunication networks
designed to remotely interpret electrocardiograms and is used by
private practice, as well as government and corporate healthcare
providers nationwide. The CardioGram delivers online
electrocardiogram interpretations within two minutes of receipt,
and has the additional capability to automatically provide an
over-read (i.e., follow- up review) by a cardiologist. CompuMed
is headquartered in Los Angeles. Visit CompuMed at
www.compumed.net .
This news release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance and
underlying assumptions and other statements that are other than
statements of historical facts. These statements are subject to
uncertainties and risks including, but not limited to, product
and service demand and acceptance, changes in technology,
ability to raise capital, availability of appropriate
acquisition candidates and/or business partnerships, economic
conditions, impact of competition and pricing, capacity and
supply constraints or difficulties, government regulation and
other risks defined in this document. All such forward-looking
statements whether written or oral, and whether made by or on
behalf of the Companies are expressly qualified by these
cautionary statements and any other cautionary statements which
may accompany the forward-looking statements. In addition, the
Company disclaims any obligation to update any forward-looking
statements to reflect events or circumstances after the date
hereof. |
| |
|
|
| |
|
|
